Short-time Safety of the Sinopharm COVID-19 Vaccine in Patients with Hemophilia
Open Access
- 30 May 2022
- journal article
- research article
- Published by Brieflands in Archives of Clinical Infectious Diseases
- Vol. 16 (6)
Abstract
Background: The COVID-19 pandemic, caused by SARS-Cov-2, has affected the care of patients with hemophilia, indicating the necessity of their vaccination. Nevertheless, there are concerns about using anti-SARS-Cov-2 virus vaccines for hemophilic patients, particularly concerning bleeding adverse events. Methods: Following a cross-sectional design, all adult hemophilic patients who received two doses of Sinopharm anti-SARS-Cov-2 virus vaccine in Afzalipour Hospital, Kerman, Iran, during May and June 2021 were recruited. The participants were followed for two weeks after receiving each dose of vaccine. Results: Fifty-one patients with a mean age of 37.07 ± 11.45 years were included, of whom 27 (61.4 %) patients experienced at least one adverse reaction. Pain was the most frequent local adverse event (occurred in 20 (39.2%) and 15 (29.4%) cases after 1st and 2nd doses, respectively). Menometrorrhagia and epistaxis were reported by two and one patients, respectively. Conclusions: Overall Sinopharm anti-SARS-Cov-2 virus vaccine seems to be safe for patients with hemophilia in the short term.Keywords
This publication has 11 references indexed in Scilit:
- The statistical risk of diagnosing coincidental acquired hemophilia A following anti‐SARS‐CoV‐2 vaccinationJournal of Thrombosis and Haemostasis, 2022
- Side effects and perceptions following Sinopharm COVID-19 vaccinationInternational Journal of Infectious Diseases, 2021
- Acquired Autoimmune Hemophilia Following SARS-CoV-2 Vaccines: Dual-Drug Effects on Blood Coagulation and the Scylla and Charybdis PhenomenonThrombosis and Haemostasis, 2021
- Autoimmunity after Coronavirus Disease 2019 (COVID-19) Vaccine: A Case of Acquired Hemophilia AThrombosis and Haemostasis, 2021
- Severe acquired haemophilia associated with asymptomatic SARS-CoV-2 infectionBMJ Case Reports, 2021
- Consensus Recommendations for Intramuscular COVID-19 Vaccination in Patients with HemophiliaHamostaseologie, 2021
- A case report of acquired hemophilia following COVID‐19 vaccineJournal of Thrombosis and Haemostasis, 2021
- Vaccination against COVID‐19: Rationale, modalities and precautions for patients with haemophilia and other inherited bleeding disordersHaemophilia, 2021
- Oxford–AstraZeneca COVID-19 vaccine efficacyThe Lancet, 2021
- Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity OutcomesJAMA, 2020